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Objectives: There is a need for alternative strategies to combat 
and prevent antibiotic-resistant bacterial infections. Here, we 
assessed the potential for bacteriophage prophylaxis in the con-
text of experimental ventilator-associated pneumonia due to meth-
icillin-resistant Staphylococcus aureus in rats.
Design: Nebulized phages (aerophages) were delivered to the 
lungs of rats using a modified vibrating mesh aerosol drug de-
livery system. Animals were intubated and ventilated for 4 hours, 
at which point they were infected with methicillin-resistant S. 
aureus strain AW7 via the endotracheal tube, extubated, and then 
monitored for 96 hours.
Setting:  Ventilator-associated pneumonia.
Subjects: Male Wistar rats.
Interventions: A single application of aerophages prior to ventila-
tion at one of two concentrations (~1010 plaque forming units/
mL or ~1011 plaque forming units/mL).
Measurements and Main Results: 1) Animal survival at 96 hours, 
2) enumeration of bacteria and phages in the lungs and spleen, 
and 3) lung tissue histopathology. Animals that received aero-
phages prior to ventilation and methicillin-resistant S. aureus 
challenge showed a higher survival rate compared with untreated 
controls (60% for animals that received 3 × 1010 plaque forming 
units; 70% for animals that received 3 × 1011 plaque forming units; 
0% for controls; p < 0.01 for each treatment versus untreated). 
Surviving animals that received aerophage prophylaxis had fewer 
methicillin-resistant S. aureus in the lungs compared with un-
treated control animals that succumbed to pneumonia (1.6 × 106 
colony forming units/g vs 8.0 × 108; p < 0.01).
Conclusions: Prophylactically administered nebulized bacterio-
phages reduced lung bacterial burdens and improved survival 
of methicillin-resistant S. aureus infected rats, underscoring its 
potential in the context of ventilator-associated pneumonia. (Crit 
Care Med 2020; XX:00–00)
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Mechanically ventilated patients are at risk of con-tracting bacterial infections, most notably ventila-tor-associated pneumonia (VAP). In light of this, 
patients often receive parenteral antibiotics in response to early 
signs of inflammation or even as means of prevention for at-
risk patients (1). At least for Staphylococcus aureus, a frequent 
contributor to infection in this setting (2, 3), systemic antibi-
otic administration does not effectively reduce the prevalence 
of VAP, likely due to the limitations of anti-staphylococcal anti-
biotics, such as poor lung penetration and limited effectiveness 
against bacterial biofilms (1, 4, 5). Additionally, topical admin-
istration of antibiotics and disinfectants have produced mixed 
results and have been associated with the spread of antibiotic 
resistance (5). Clearly, antibiotic alternatives warrant investiga-
tion for the prevention of VAP due to S. aureus.
One strategy is the application of bacterial viruses known 
as phage therapy, which has been rediscovered for the treat-
ment of many diverse, antibiotic-resistant infections (for a 
recent review, see reference [6]). In the context of VAP, in-
travenously administered phages have been shown to be as 
effective as standard of care antibiotics for the treatment of 
pneumonia due to methicillin-resistant S. aureus (MRSA) in 
an experimental model of VAP in rats (7). Phages have the 
added benefits of effectiveness against bacterial biofilms, and 
mechanisms of action that are distinct from typical antibiotics, 
which limits the threat of antibiotic resistance (8). Important DOI: 10.1097/CCM.0000000000004352
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questions relating to phage therapy remain, including when, 
how and how many bacteriophages should be delivered (8, 9). 
In the current report, we have assessed the utility of nebulized 
bacteriophages (“aerophages”) for prophylaxis of VAP due to 
MRSA in an experimental rat model.
MATERIALS AND METHODS
All animal experiments were approved by the Cantonal Com-
mittee on Animal Experiments of the State of Bern, Switzer-
land (approval BE 53/19). We first addressed the bioavailability 
of aerophages over a 24-hour period in uninfected Wistar rats 
(male, 300–400 g). Twelve animals were administered 3 mL of a 
multiphage cocktail (consisting of phages K, 3A, 2002 and 2003 
at final concentration of 1 × 1010 plaque forming units [PFUs] 
per mL) using a modified vibrating mesh aerosol drug delivery 
system (Aerogen Solo, Aerogen, Ireland). Animals anesthe-
tized with sevoflurane (Fi 1–3%) were connected to the neb-
ulizer via a facemask and aerophages were delivered inside an 
enclosed induction chamber. Following aerophage application, 
animals were returned to their cages. Animals were euthanized 
at 0, 2, 6, and 24 hours (n = 3 per time point) at which point 
the lungs were homogenized and phages were quantified in 
double-layer agar plates as described previously (7). To deter-
mine if increasing the number of aerophages would improve 
experimental outcomes, the phage cocktail was concentrated 
via isopycnic ultracentrifugation through a caesium chloride 
(CsCl
2
) gradient, the residual CsCl
2
 was removed via filtration 
(Amicon Ultra Centrifugal Filters; Merck, Germany), and the 
phages were resuspended in 0.9% sodium chloride to a final 
concentration of 1 × 1011 PFU/mL. To address bioavailability, 
animals (n = 4) were administered 3 mL of the 1 × 1011 PFU/ml 
cocktail, euthanized, and phages in the lungs were quantified 
as described above.
We next employed our established model of severe MRSA 
VAP essentially as described elsewhere (7). Briefly, animals (n = 
10 per treatment group) received a single dose of either 3 × 1010 
PFU or 3 × 1011 PFU of aerophages as described above and were 
returned to their cages. After 2 hours, animals were ventilated 
for 4 hours on ventilators for small animals (VentElite; Harvard 
Apparatus [Holliston, MA]; 10 mL/kg tidal volume, 5 cm H
2
O 
of positive end-expiratory pressure, 50 breaths/min with Fio
2
 
0.35). Anesthesia was maintained with inhaled sevoflurane (Fi 
3–4%) with additional subcutaneous fentanyl (20 µg/kg) deliv-
ered every 30–60 minutes. A total of 6 hours after aerophage 
prophylaxis, animals were inoculated with ~8 × 109 colony 
forming units of an alpha-toxin producing clinical MRSA 
strain (AW7) via the endotracheal tube and were then extu-
bated. Animal welfare was determined at least three times per 
day over the course of 96 hours, and the severity of illness was 
scored using an animal welfare scoring system (Supplemental 
Table 1, Supplemental Digital Content 1, http://links.lww.com/
CCM/F449). Animals were euthanized with pentobarbital 
(150 mg/kg) if they scored greater than “1,” or if their weight 
decreased by more than 20% (classed as “non-survivors”) (7). 
Remaining animals were euthanized at 96 hours and classed 
as “survivors.” Quantification of MRSA burdens in the lungs 
and spleen was performed following tissue homogenization 
as described previously (7). Histopathological analyses were 
performed as described previously (7), and a histopatholog-
ical score was calculated for lung tissues according to param-
eters detailed in Supplemental Table 2 (Supplemental Digital 
Content 1, http://links.lww.com/CCM/F449). Infected and un-
treated animals (n = 7) were included as controls to validate 
the lethality of the model.
RESULTS
A single application of 3 × 1010 PFU of aerophages to the air-
ways of uninfected rats resulted in moderate phage loads in 
the lungs immediately after administration (1 × 106 PFU/g; 
Fig. 1A), and a phage lung burden was still apparent at 24 hours 
(4 × 104 PFU/g; Fig. 1B). Application of a higher dose (3 × 1011 
PFU) to uninfected animals resulted in an average phage load 
for the lungs of 6 × 106 PFU/g soon after application (Fig. 1A).
In the context of experimental VAP due to MRSA, all con-
trol animals showed severe symptoms and succumbed to infec-
tion within 48 hours (Fig. 1C). A single application of 3 × 1010 
PFU of aerophages prior to ventilation and infection prevented 
mortality in 60% of animals (Fig. 1C; p < 0.01 compared with 
untreated controls; log-rank test). Administration of 3 × 1011 
PFU prior to ventilation rescued 70% of animals, which was 
higher than for untreated animals (p < 0.01; log-rank test), 
but survival was not statistically different compared with those 
that received the lower dose of phages (p = 0.66).
Mortality in experimental models of VAP due to MRSA cor-
relates with high bacterial loads in the lungs (7). In support of 
this, surviving animals treated with prophylactic aerophages 
had ~500 times less MRSA in the lungs compared with either 
untreated controls, or treated animals that succumbed to in-
fection (Fig. 2A; p < 0.01 using one-way analysis of variance 
[ANOVA]; and p < 0.01 for each comparison using Tukey 
multiple comparisons test). When lung bacterial loads were 
compared between control animals and each phage treatment 
group, no significant differences were determined, likely owing 
to the high MRSA loads for the nonsurviving animals present 
in each group (Fig. 2B; p = 0.17; one way ANOVA). There was a 
positive correlation between bacterial burden in the lungs and 
histopathological scoring of the lung tissue for animals that re-
ceived phage prophylaxis (Fig. 2C; r = 0.80; p < 0.0001; Pearson 
two-tailed correlation test). MRSA loads for the spleen, which 
we use as a marker for the systemic spread of infection, were not 
different between surviving and nonsurviving animals (Fig. 2D; 
p = 0.24; one-way ANOVA) or between treatment groups (Fig. 
2E; p = 0.88; one-way ANOVA). Phages were recovered from 
the lungs of most of the phage treated animals after euthanasia 
(17/20; Fig. 2F), and were infrequently detected in the spleen 
(1/20 animals) suggesting aerophages remain localized in the 
lung tissue and do not readily spread to other organs.
DISCUSSION AND CONCLUSIONS
A single, prophylactic application of a nebulized phage cock-
tail prior to ventilation prevented lethal infection for the 
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majority of animals in an experimental model of VAP due 
to MRSA (Fig. 1). Survival was associated with substantial 
decreases in bacterial burden in the lungs and reduced lung 
tissue damage (Fig. 2). The results of the current report pro-
vide an important proof-of-concept for phage prophylaxis in 
the context of VAP. Although we observed promising results 
for laboratory animals in a controlled study, the distribution 
of phages and effectiveness of prophylaxis in severely dam-
aged and heterogeneously ventilated lungs of human patients 
remains to be determined.
Phage prophylaxis joins a small but expanding list of 
appealing antibiotic alternatives that may be effective for 
VAP prevention. Generally, probiotics have shown promise in 
mechanically ventilated patients, whereby inoculation with 
Lactobacillus proved to be effective at reducing the prevalence 
of VAP in a placebo-controlled trial, irrespective of the caus-
ative organism (10). When focusing on MRSA, monoclonal 
antibodies that can neutralize S. aureus toxins have shown 
promise for the prevention of pneumonia in animal models 
(11), they are safe and well-tolerated in healthy human adults 
(12), and are being investigated in an interventional clinical 
trial for the prevention of pneumonia in high-risk patients 
(NCT02296320).
Our current findings pave the way for future phase I/II tri-
als that will address safety, dosing and tolerability of phages in 
patients at risk of MRSA VAP including those colonized with 
S. aureus, and expected to require prolonged ventilation (i.e., 
longer than 48 hr).
Figure 1. Aerophages for prophylaxis of experimental ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA).  
A, Bioavailability of phages in the lungs immediately after nebulized delivery of either 3 × 1010 plaque forming units (PFUs) (blue symbols) or 3 × 1011 
PFU (green symbols) of a phage cocktail (aerophage) and (B) over the course of 24 hr (only for 3 × 1010 PFU of aerophages). C, Kaplan-Meier survival 
curves for MRSA infected animals with and without (black line) aerophage prophylaxis. Significance was determined using log-rank tests, **p < 0.01.
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